{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:14:27Z","timestamp":1738732467751,"version":"3.37.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jctube.2024.100429","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:50:27Z","timestamp":1710525027000},"page":"100429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Acquired rifamycin resistance among patients with tuberculosis and HIV in New York City, 2001\u20132023"],"prefix":"10.1016","volume":"35","author":[{"given":"Felicia","family":"Dworkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-9415","authenticated-orcid":false,"given":"Alice V.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2024.100429_b0005","unstructured":"Global tuberculosis report 2022. World Health Organization: Geneva. Licence: CC BY-NC-SA 3.0 IGO.; 2022."},{"issue":"6","key":"10.1016\/j.jctube.2024.100429_b0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins","volume":"53","author":"Regazzi","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jctube.2024.100429_b0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jctube.2024.100429_b0020","doi-asserted-by":"crossref","unstructured":"Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207; quiz CE1-4.","DOI":"10.1037\/e537722009-001"},{"key":"10.1016\/j.jctube.2024.100429_b0025","unstructured":"CDC DTBE. TB Treatment for Persons with HIV [Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbhiv.htm."},{"issue":"7","key":"10.1016\/j.jctube.2024.100429_b0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw566","article-title":"Executive Summary: official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical Practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.jctube.2024.100429_b0035","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJM199606133342404","article-title":"Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis","volume":"334","author":"Bishai","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jctube.2024.100429_b0040","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jctube.2024.100429_b0045","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/516065","article-title":"Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis","volume":"25","author":"March","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jctube.2024.100429_b0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1164\/ajrccm.152.3.7663785","article-title":"Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis","volume":"152","author":"Nolan","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"6 Pt 1","key":"10.1016\/j.jctube.2024.100429_b0055","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1164\/ajrccm.157.6.9712009","article-title":"Risk factors for rifampin mono-resistant tuberculosis","volume":"157","author":"Ridzon","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"9167","key":"10.1016\/j.jctube.2024.100429_b0060","first-page":"1843","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid","volume":"353","author":"Vernon","year":"1999","journal-title":"Tuberculosis Trials Consortium Lancet"},{"issue":"1","key":"10.1016\/j.jctube.2024.100429_b0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/430377","article-title":"Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997\u20132000","volume":"41","author":"Li","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jctube.2024.100429_b0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/ajrccm.153.2.8564140","article-title":"Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS","volume":"153","author":"Lutfey","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jctube.2024.100429_b0075","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/cid\/cis989","article-title":"Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994\u20132006","volume":"56","author":"Porco","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jctube.2024.100429_b0080","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciu674","article-title":"Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy","volume":"59","author":"Narendran","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jctube.2024.100429_b0085","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/QAD.0b013e32835521a3","article-title":"The history of antiretroviral therapy and of its implementation in resource-limited areas of the world","volume":"26","author":"Vella","year":"2012","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jctube.2024.100429_b0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jctube.2024.100429_b0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/381675","article-title":"Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use","volume":"38","author":"Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jctube.2024.100429_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"year":"1999","series-title":"Bureau of Tuberculosis Control, New York City Department of Health","author":"Clinical Policies and Protocols","key":"10.1016\/j.jctube.2024.100429_b0105"},{"year":"2022","series-title":"Bureau of Tuberculosis Control, New York City Department of Health","author":"Policies","key":"10.1016\/j.jctube.2024.100429_b0110"},{"issue":"9","key":"10.1016\/j.jctube.2024.100429_b0115","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jctube.2024.100429_b0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2024.100429_b0125","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1128\/JCM.00298-17","article-title":"Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York state","volume":"55","author":"Shea","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jctube.2024.100429_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0040-2016","article-title":"Impact of the GeneXpert MTB\/RIF technology on tuberculosis control","volume":"5","author":"Stevens","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jctube.2024.100429_b0135","article-title":"Rifampin mono-resistant tuberculosis in New York City, 2010\u20132021: a retrospective case series. open forum","volume":"10(11):ofad534","author":"Lindsey","year":"2023","journal-title":"Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2024.100429_b0140","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2242","article-title":"HIV viral suppression trends over time among HIV-infected patients receiving Care in the United States, 1997 to 2015: a cohort study","volume":"169","author":"Nance","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579424000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579424000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:20:25Z","timestamp":1738729225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579424000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"alternative-id":["S2405579424000160"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2024.100429","relation":{},"ISSN":["2405-5794"],"issn-type":[{"type":"print","value":"2405-5794"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired rifamycin resistance among patients with tuberculosis and HIV in New York City, 2001\u20132023","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2024.100429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100429"}}